Dimension Capital launches $800M fund targeting AI-driven drug discovery

Dimension Capital is raising $800 million to invest in AI-designed pharmaceuticals despite the lack of current regulatory approvals for such products. This move highlights growing venture capital confidence in AI's potential to accelerate drug development pipelines, though the long-term commercial viability remains unproven.